CGP-74514A

CAS No. 190653-73-7

CGP-74514A ( CGP 74514A;CGP74514A )

Catalog No. M12989 CAS No. 190653-73-7

A potent, dual CDC-like kinase (CLK)/CDK inhibitor with IC50 of 148, 111, 104, 382 and 573 nM for CLK1, CLK2, CLK4, CDK1 and CDK4, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    CGP-74514A
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent, dual CDC-like kinase (CLK)/CDK inhibitor with IC50 of 148, 111, 104, 382 and 573 nM for CLK1, CLK2, CLK4, CDK1 and CDK4, respectively.
  • Description
    A potent, dual CDC-like kinase (CLK)/CDK inhibitor with IC50 of 148, 111, 104, 382 and 573 nM for CLK1, CLK2, CLK4, CDK1 and CDK4, respectively.
  • Synonyms
    CGP 74514A;CGP74514A
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    CLK
  • Recptor
    CLK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    190653-73-7
  • Formula Weight
    385.90
  • Molecular Formula
    C19H24ClN7
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CCN1C=NC2=C(N=C(N=C21)NC3CCCCC3N)NC4=CC(=CC=C4)Cl
  • Chemical Name
    N2-((1R,2S)-2-aminocyclohexyl)-N6-(3-chlorophenyl)-9-ethyl-9H-purine-2,6-diamine

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Shi Y, et al. Bioorg Med Chem Lett. 2017 Feb 1;27(3):406-412.
molnova catalog
related products
  • MU1210

    MU1210 (MU-1210) is a potent and highly selective inhibitor of cdc-like kinases (CLKs) with IC50 of 51 nM.

  • Leucettamine B

    Leucettamine B is a potent inhibitor of CLK1 (IC50=15 nM), Dyrk1A (IC50=40 nM), and Dyrk2 (IC50=35 nM) and a moderate inhibitor of CLK3 (IC50=4.5 uM).

  • K00546

    K00546 is a potent inhibitor of the CDC2-like kinase CLK1 and CLK3 with IC50 of 8.9 and 29.2 nM, respectively.